Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MANE
SellSinkerVeradermics, Incorporated · Healthcare · United States · $4.1B · Avg Vol: $72M/d
22
StockRankGet insider-trade alerts
Q
32
V
26
M
50
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — | — | 8.7M | — |
| EPS | -1.51 | -1.37 | -2.00 | — | -2.49 | -2.94 | -2.69 | — |
| Shares | 35.1M | 35.1M | 37.3M | +6.5% | 41.8M | — | — | — |
| Debt | 0.8M | 0 | 4.0K | -92.9% | 0.4M | — | — | — |
| Equity | -22.2M | -48.5M | -121.0M | — | — | — | — | — |
| Op CF | -13.5M | -23.7M | -71.6M | — | -78.3M | — | — | — |
| Inv CF | — | 0 | -118.9M | — | — | — | — | — |
| Fin CF | 13.9M | 60.5M | 159.1M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-7.5%
SMA 50SMA 200
Close
$99.67
RSI (14)
33.6
SCORE BREAKDOWN
Quality
32
ROIC
-48.8%16.4
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-46.9%7.3
Piotroski
29.5
Int. Cover
—N/A
D/E Ratio
0.00x94.7
Current Ratio
70.53x99.5
Value
26
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
5.1x28.2
P/S
—N/A
Div Yield
—N/A
Momentum
50
52W High %
—N/A
RS 6M
84%95.6
SMA 50/200
—N/A
EPS Rev 4W
+11.8%90.7
EPS Rev 12W
—N/A
EPS Improve
-8%18.9
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$4.1B
P/E (Forward)
-36.7x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MANE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MANE | Veradermics, Incorporated(you) | $4.1B | 22 | Sell |
| IDYA | IDEAYA Biosciences, Inc. | $3.9B | 21 | Sell |
| DNLI | Denali Therapeutics Inc. | $3.8B | 21 | Sell |
| VKTX | Viking Therapeutics, Inc. | $3.8B | 18 | Strong Sell |
| TNGX | Tango Therapeutics, Inc. | $3.9B | 17 | Strong Sell |
| IRON | Disc Medicine, Inc. | $3.1B | 22 | Sell |
| DFTX | Definium Therapeutics, Inc. | $5.5B | 22 | Sell |
| RLAY | Relay Therapeutics, Inc. | $4.1B | 28 | Sell |
| IMNM | Immunome, Inc. | $3.1B | 20 | Strong Sell |
| EWTX | Edgewise Therapeutics, Inc. | $4.6B | 28 | Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%